The European Medicines Agency guidance highlights key principles and examples of good practices to prevent and manage shortages of human medicines.
The European Medicines Agency (EMA) released guidance detailing guidelines for patient and healthcare professional organizations on the prevention and management of shortages of medicines for human use on July 15, 2022. Identifying shortages and reduced availability as an increasing issue that has been amplified by the COVID-19 pandemic. The guidance seeks to present key recommendations for these situations.
Recommendations have been prepared based on consultations with member organizations of the EMA Patients’ and Consumers’ Working Party and Healthcare Professionals’ Working Party.Many of these recommendations draw on existing practices and initiatives in individual European Union member states where the suggested practices have been implemented, often in isolation.
Some key recommendations from the guidance suggest that relevant organizations should:
The full guidance can be read here.
Source: EMA
Texas' MD Anderson Cancer Center Creates New Cell Therapy Institute
November 11th 2024With the launch of the Institute for Cell Therapy Discovery and Innovation, the MD Anderson Cancer Center will bring together expertise in developing cell therapies for cancer, autoimmune diseases, and infections.